TruScreen Group Ltd. (TRU) AI Stock Analysis

TruScreen Group Ltd.

(NZX:TRU)

Select Model

Rating:44Neutral

Price Target:NZD 0.01▲(0.00% Upside)

Action:initiatedcoverage

Date:10/05/26

The score is primarily held back by weak financial performance—especially the sharp gross margin collapse, large ongoing losses, and persistent negative free cash flow that increases funding risk. Technicals also lean bearish with price below all major moving averages and negative MACD. Valuation provides limited support because the negative P/E reflects losses and dividend yield data is unavailable.

Positive Factors

Revenue reboundThe strong FY2026 revenue rebound indicates renewed demand for TruScreen’s screening systems and consumables. If this growth persists, a larger installed base and broader program adoption could improve operating leverage and provide a stronger foundation for future commercial scale.

Negative Factors

Gross margin collapseThe sharp gross-margin deterioration shows that recent revenue growth has not translated into attractive unit economics. Unless margins recover, additional sales may contribute little toward fixed costs, limiting scalability and weakening the economic durability of the business model.

TruScreen Group Ltd. (TRU) vs. SPDR S&P 500 ETF (SPY)

Market Cap: NZD 5.65M
Dividend Yield: ―
Average Volume (3M): 692.70K
Price to Earnings (P/E): -2.9
Beta (1Y): -0.23
Revenue Growth: 42.20%
EPS Growth: 23.68%
Country: NZ
Employees: 6
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

TruScreen Group Ltd. Business Overview & Revenue Model

Company Description

TruScreen Group Limited, alongside its subsidiaries, focuses on the development, manufacturing, and global distribution of advanced systems for cancer detection. Their commercial reach extends across various international territories, including Mexic...

TruScreen Group Ltd. Financial Statement Overview

Summary

Despite a strong FY2026 revenue rebound (+58% vs FY2025), profitability and cash generation are very weak. FY2026 gross margin collapsed to ~1% and the company continues to post large operating/net losses (net margin about -93%), while operating cash flow and free cash flow remain consistently negative and deteriorated in FY2026—raising ongoing funding risk. The balance sheet is a relative bright spot with modest leverage (debt-to-equity ~0.08), but persistently negative ROE (roughly -87%) signals continuing capital pressure.

Income Statement

18Very Negative

Balance Sheet

57Neutral

Cash Flow

24Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	2.43M	2.43M	1.71M	2.60M	1.66M	1.68M
Gross Profit	25.48K	25.48K	515.22K	1.16M	459.99K	522.74K
EBITDA	-2.64M	-2.64M	-2.12M	-2.55M	-2.51M	-7.94M
Net Income	-2.25M	-2.25M	-2.24M	-2.05M	-2.40M	-7.89M
Balance Sheet
Total Assets	3.75M	3.75M	1.85M	4.03M	3.47M	4.39M
Cash, Cash Equivalents and Short-Term Investments	1.46M	1.46M	365.47K	2.73M	2.16M	2.80M
Total Debt	200.69K	200.69K	317.37K	0	0	0
Total Liabilities	1.16M	1.16M	839.98K	798.45K	928.16K	991.89K
Stockholders Equity	2.59M	2.59M	1.01M	3.23M	2.54M	3.40M
Cash Flow
Free Cash Flow	-2.47M	-2.47M	-2.29M	-2.03M	-2.24M	-2.53M
Operating Cash Flow	-2.47M	-2.47M	-2.29M	-2.03M	-2.19M	-2.53M
Investing Cash Flow	0	0	0	0	-49.70K	-2,662
Financing Cash Flow	3.49M	3.49M	-84.40K	2.58M	1.55M	0

TruScreen Group Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price0.01

Price Trends

50DMA0.01Negative

100DMA0.02Negative

200DMA0.02Negative

Market Momentum

MACD-0.00Positive

RSI38.34Neutral

STOCH38.89Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:TRU, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 38.34 is Neutral, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NZ:TRU.

TruScreen Group Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

NZ:TRU against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NZ:FPH	80Outperform	NZD 28.04B	59.58	22.84%	1.59%	15.59%	23.94%
NZ:EBO	70Outperform	NZD 4.29B	15.33	7.99%	6.01%	16.36%	5.52%
NZ:AFT	54Neutral	NZD 487.67M	32.88	14.07%	0.63%	22.44%	23.14%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NZ:OCA	50Neutral	NZD 463.51M	3020.43	0.02%	―	2.52%	-99.52%
NZ:TRU	44Neutral	NZD 9.43M	-2.90	-75.57%	―	42.20%	23.68%
NZ:PEB	42Neutral	NZD 291.84M	-6.13	-190.54%	―	-47.36%	-3.79%

* Healthcare Sector Average

Performance Comparison

NZ:TRU and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
NZ:TRU	TruScreen Group Ltd.	0.01	-0.01	-47.37%
NZ:EBO	EBOS Group Limited	20.50	-6.83	-24.99%
NZ:FPH	Fisher & Paykel Healthcare Corporation Limited	47.66	11.50	31.79%
NZ:OCA	Oceania Healthcare Ltd.	0.64	-0.16	-20.00%
NZ:PEB	Pacific Edge Limited	0.23	0.04	21.76%
NZ:AFT	AFT Pharmaceuticals Ltd.	4.65	1.62	53.67%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 05, 2026

TruScreen Group Ltd. AI Stock Analysis